The only FDA-approved therapy for stroke is IV administration of tissue plasminogen activator (tPA); however, it is available to patients that present within 4.5 h of stroke onset, and only 5–8% of patients qualify for this therapy2. The gene discussed is PLAT; the disease is stroke disorder.